Medeor Therapeutics Overview
- Year Founded
-
2012
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
Medeor Therapeutics General Information
Description
Developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve kidney transplant function and prevent graft rejection without currently available immunosuppressive (anti-rejection) drugs.
Contact Information
Website
www.medeortx.comCorporate Office
- 611 Gateway Boulevard
- Suite 120
- South San Francisco, CA 94080
- United States
Corporate Office
- 611 Gateway Boulevard
- Suite 120
- South San Francisco, CA 94080
- United States
Medeor Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Secondary Transaction - Private | 01-Feb-2026 | Completed | Clinical Trials - Phase 3 | |||
| 6. Debt - PPP | 29-Apr-2020 | Completed | Clinical Trials - Phase 3 | |||
| 5. Grant | 22-Jan-2018 | Completed | Clinical Trials - Phase 3 | |||
| 4. Later Stage VC (Series B) | 27-Nov-2017 | Completed | Clinical Trials - Phase 3 | |||
| 3. Early Stage VC (Series A) | 16-Oct-2015 | Completed | Clinical Trials - Phase 3 | |||
| 2. Early Stage VC | 02-Oct-2013 | $1.55M | $2.55M | Completed | Clinical Trials - Phase 3 | |
| 1. Seed Round | 11-Jan-2013 | $1M | $1M | Completed | Clinical Trials - Phase 3 |
Medeor Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Seed 1 | 1,291,667 | $0.000100 | 8% | $1.2 | $1.2 | 1x | $1.2 | 4.67% |
| Seed | 1,000,000 | $0.000100 | 8% | $1 | $1 | 1x | $1 | 3.61% |
Medeor Therapeutics Patents
Medeor Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240108655-A1 | Methods of producing mixed chimerism after a solid organ transplant | Pending | 13-Sep-2022 | ||
| US-20230201256-A1 | Calcineurin inhibitor to improve cd3+cell survival to thereby facilitate engraftment of donor cd34+ cells in a recipient | Inactive | 21-May-2020 | ||
| WO-2021236711-A1 | Calcineurin inhibitor to improve cd3+cell survival to thereby facilitate engraftment of donor cd34+ cells in a recipient | Inactive | 21-May-2020 | ||
| US-20220305057-A1 | Methods of making cellular products by post- mortem mobilization and harvesting of hematopoietic cells | Inactive | 06-Jun-2019 | ||
| EP-3980036-A1 | Methods of making cellular products by post-mortem mobilization and harvesting of hematopoietic cells | Inactive | 06-Jun-2019 | A61K35/28 |
Medeor Therapeutics FAQs
-
When was Medeor Therapeutics founded?
Medeor Therapeutics was founded in 2012.
-
Where is Medeor Therapeutics headquartered?
Medeor Therapeutics is headquartered in South San Francisco, CA.
-
What industry is Medeor Therapeutics in?
Medeor Therapeutics’s primary industry is Drug Discovery.
-
Is Medeor Therapeutics a private or public company?
Medeor Therapeutics is a Private company.
-
What is Medeor Therapeutics’s current revenue?
The current revenue for Medeor Therapeutics is .
-
How much funding has Medeor Therapeutics raised over time?
Medeor Therapeutics has raised $67.5M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process